Companies › Aphaia Pharma US
2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| APHD-002 Distal jejunal-release dextrose beads | – | Phase 2 | Obese With Comorbidities | – |
| APHD-012 Distal jejunal-release dextrose beads | – | Phase 2 | Obese With Comorbidities | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07008456 | APHD-012 | Phase 2 | Obese With Comorbidities | Metabolic and endocrine | Jul 2026 |
| NCT07008456 | APHD-002 | Phase 2 | Obese With Comorbidities | Metabolic and endocrine | Jul 2026 |
No annotated target.
–
Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Portal Therapeutics Op-T Housey Healthcare ULC
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.